FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Ranked reports inside the event cluster. Open any publisher link to read the original coverage.
Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.
The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
Increased targeting of oil and gas infrastructure in the Iran war is hitting trader sentiment hard as concerns mount that the current energy crisis is going to have a lasting impact on the global economy.
As Gulf state leaders gathered in a Riyadh hotel this week to discuss the growing Middle East war, strikes from Tehran blasted outside.
The IEA warns of "the largest supply disruption in the history of the global oil market" due to the conflict in the Middle East.
Strikes on key Gulf energy sites are becoming more frequent and more damaging, beginning to unsettle supply and expose vulnerabilities across the region.
India's IIBX Bullion Exchange – Price Taker or Price Maker?